fibriinogeenitasot

Fibriinogeenitasot refers to the concentration of fibrinogen in blood plasma. Fibrinogen is a soluble glycoprotein produced mainly by the liver. It is converted by thrombin into fibrin, forming the mesh that stabilizes a blood clot. As an acute-phase protein, fibrinogen levels can rise in inflammation, infection, tissue injury and pregnancy, and fall in some liver diseases or disseminated intravascular coagulation.

Measurement and reference ranges: Fibrinogen is measured from citrated plasma with clot-based assays (Clauss method) or with immunological methods. Typical reference values are about 2-4 g/L (200-400 mg/dL), but exact ranges vary by laboratory and method. Pregnancy and oral contraceptives may shift normal values upward modestly.

Clinical significance: Low fibrinogen (hypofibrinogenemia) can impair clot formation and lead to excessive bleeding. It may be congenital (afibrinogenemia) or acquired, as in liver disease, severe DIC, or massive blood loss. High fibrinogen (hyperfibrinogenemia) is associated with increased risk of thrombosis and is commonly seen in inflammatory states; it is also linked to cardiovascular risk. Because fibrinogen is an acute-phase reactant, levels may be elevated in infections, smoking, obesity, and pregnancy.

Clinical use and interpretation: Fibrinogen level is often included in coagulation workups alongside prothrombin time (PT), activated partial thromboplastin time (aPTT) and platelet count. Clinicians interpret results in the context of symptoms, other tests, and patient risk factors. In some settings, functional fibrinogen (Clauss) and fibrinogen antigen (immunologic) assays may yield different information about quantity versus function.